Table 1.

Summary of clinical characteristics of healthy controls and patients with myeloid malignancies

Characteristic	Myeloid patients (N = 48)	Healthy controls (N = 16)
Median age (range), y	70 (28-89)	34.5 (21-75)
Sex	27 males/21 females	5 males/11 females
Diagnosis
MDS	N = 23
AML	N = 13
CMML	N = 1
Jak2^V617F+ MPN
ET	N = 1
PV	N = 6
MF	N = 4
Treatment
Observation/growth factors	N = 16
HMA (azacitidine or decitabine) monotherapy	N = 7
HMA/venetoclax	N = 10
HMA/other	N = 4
Allo-BMT	N = 2
Peginterferon	N = 1
Hydroxyurea	N = 3
Ruxolitinib	N = 3
Ruxolitinib/hydroxyurea	N = 1
Anagrelide	N = 1
Vaccines/boosters
Moderna (second vaccine)	N = 19	N = 8
Pfizer (second vaccine)	N = 18	N = 8
Janssen (1 vaccine)	N = 1
Same mRNA second and third vaccines	N = 9	N = 8
Mixed mRNA second and third vaccines (Moderna-Pfizer)	N = 1	N = 8
Documented breakthrough SARS-CoV-2 infection	N = 3
Median time of sample collection from second vaccine dose	150.5 d	38 d
Median time of sample collection from third vaccine dose	30.5 d	57.5 d

AML, acute myeloid leukemia; BMT, bone marrow transplant; CMML, chronic myelomonocytic leukemia; ET, essential thrombocytopenia; HMA, hypomethylating agent; MF, myelofibrosis; PV, polycythemia vera.